15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Grapiprant (Primary) ; Gemcitabine
- Indications Advanced breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- 03 Jun 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jun 2017.
- 03 Jun 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 May 2016 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.